Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity.


Journal

The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125

Informations de publication

Date de publication:
01 Jan 2021
Historique:
pubmed: 24 10 2020
medline: 5 1 2021
entrez: 23 10 2020
Statut: ppublish

Résumé

Using moderate or ultra-hypofractionation, which is also known as stereotactic body radiotherapy (SBRT) for treatment of localized prostate cancer patients has been increased. We present our preliminary results on the clinical utilization of MRI-guided adaptive radiotherapy (MRgRT) for prostate cancer patients with the workflow, dosimetric parameters, toxicities and prostate-specific antigen (PSA) response. 50 prostate cancer patients treated with ultra-hypofractionation were included in the study. Treatment was performed with intensity-modulated radiation therapy (step and shoot) technique and daily plan adaptation using MRgRT. The SBRT consisted of 36.25 Gy in 5 fractions with a 7.25 Gy fraction size. The time for workflow steps was documented. Patients were followed for the acute and late toxicities and PSA response. The median follow-up for our cohort was 10 months (range between 3 and 29 months). The median age was 73.5 years (range between 50 and 84 years). MRgRT was well tolerated by all patients. Acute genitourinary (GU) toxicity rate of Grade 1 and Grade 2 was 28 and 36%, respectively. Only 6% of patients had acute Grade 1 gastrointestinal (GI) toxicity and there was no Grade ≥ 2 GI toxicity. To date, late Grade 1 GU toxicity was experienced by 24% of patients, 2% of patients experienced Grade 2 GU toxicity and 6% of patients reported Grade 2 GI toxicity. Due to the short follow-up, PSA nadir has not been reached yet in our cohort. In conclusion, MRgRT represents a new method for delivering SBRT with markerless soft tissue visualization, online adaptive planning and real-time tracking. Our study suggests that ultra-hypofractionation has an acceptable acute and very low late toxicity profile. MRgRT represents a new markerless method for delivering SBRT for localized prostate cancer providing online adaptive planning and real-time tracking and acute and late toxicity profile is acceptable.

Identifiants

pubmed: 33095670
doi: 10.1259/bjr.20200696
pmc: PMC7774684
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20200696

Références

Lancet. 2019 Aug 3;394(10196):385-395
pubmed: 31227373
Br J Radiol. 2016 Dec;89(1068):20160348
pubmed: 27748126
Radiother Oncol. 2007 May;83(2):163-7
pubmed: 17499871
Radiother Oncol. 2016 Jan;118(1):112-7
pubmed: 26796591
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e377-83
pubmed: 21514068
Radiother Oncol. 2013 Nov;109(2):217-21
pubmed: 24060175
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):361-373
pubmed: 29353654
Radiat Oncol. 2013 May 13;8:118
pubmed: 23668632
Cureus. 2015 Dec 04;7(12):e395
pubmed: 26798571
JAMA. 2015 Sep 22-29;314(12):1291-3
pubmed: 26393854
Lancet Oncol. 2016 Aug;17(8):1061-1069
pubmed: 27339116
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1140-50
pubmed: 16198506
J Clin Oncol. 2016 Jul 10;34(20):2325-32
pubmed: 27044935
Radiother Oncol. 2006 Dec;81(3):284-90
pubmed: 17125866
Acta Oncol. 2012 Nov;51(8):963-74
pubmed: 22966812
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):473-480
pubmed: 28463167
Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105
pubmed: 12128107
Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):909-14
pubmed: 20732764
J Clin Oncol. 2006 May 1;24(13):1990-6
pubmed: 16648499
Cureus. 2019 Dec 24;11(12):e6457
pubmed: 32025388
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Radiat Oncol. 2020 Mar 23;15(1):69
pubmed: 32248826
Lancet Oncol. 2019 Nov;20(11):1531-1543
pubmed: 31540791
Radiat Oncol. 2011 Jan 10;6:3
pubmed: 21219625
J Clin Oncol. 2015 Feb 1;33(4):332-9
pubmed: 25534388
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1013-21
pubmed: 20447774
Front Oncol. 2015 Jan 22;4:369
pubmed: 25657929
Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):339-44
pubmed: 24411606
Clin Oncol (R Coll Radiol). 2017 Mar;29(3):161-170
pubmed: 27780694
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1086-1094
pubmed: 31419510
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):587-94
pubmed: 16690440
JAMA Netw Open. 2019 Feb 1;2(2):e188006
pubmed: 30735235
Lancet Oncol. 2007 Jun;8(6):475-87
pubmed: 17482880
Pract Radiat Oncol. 2021 Jan-Feb;11(1):e11-e21
pubmed: 32739438
J Clin Oncol. 2018 Oct 11;:JCO1801097
pubmed: 30307776
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Radiat Oncol. 2017 Sep 7;12(1):149
pubmed: 28882187

Auteurs

Gamze Ugurluer (G)

Department of Radiation Oncology, Acıbadem MAA University School of Medicine, Istanbul, Turkey.

Banu Atalar (B)

Department of Radiation Oncology, Acıbadem MAA University School of Medicine, Istanbul, Turkey.

Teuta Zoto Mustafayev (T)

Department of Radiation Oncology, Acıbadem MAA University School of Medicine, Istanbul, Turkey.

Gorkem Gungor (G)

Department of Radiation Oncology, Acıbadem MAA University School of Medicine, Istanbul, Turkey.

Gokhan Aydin (G)

Department of Radiation Oncology, Acıbadem MAA University School of Medicine, Istanbul, Turkey.

Meric Sengoz (M)

Department of Radiation Oncology, Acıbadem MAA University School of Medicine, Istanbul, Turkey.

Ufuk Abacioglu (U)

Department of Radiation Oncology, Acıbadem MAA University School of Medicine, Istanbul, Turkey.

Mustafa Bilal Tuna (MB)

Department of Urology, Acıbadem Maslak Hospital, Istanbul, Turkey.

Ali Riza Kural (AR)

Department of Urology, Acıbadem MAA University School of Medicine, Istanbul, Turkey.

Enis Ozyar (E)

Department of Radiation Oncology, Acıbadem MAA University School of Medicine, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH